| Phase 3 |
| NCT06182774 |
Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older… |
Multiple Myeloma |
Recruiting |
2026-10-14 |
| NCT06641791 |
Palliative Steroeotactic Body Radiotherapy vs Palliative Standard Radiotherapy in… |
Advanced Head and Neck Cancer |
Recruiting |
2026-10-14 |
| NCT06391242 |
Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy for Painful… |
Cancer Metastatic |
Recruiting |
2026-08-11 |
| NCT05451004 |
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized… |
Oropharyngeal Cancer |
Recruiting |
2026-07-14 |
| NCT06205485 |
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer |
Rectal Cancer |
Recruiting |
2026-07-14 |
| NCT06592924 |
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration… |
Prostate Cancer (Adenocarcinoma) |
Recruiting |
2026-07-14 |
| NCT06686771 |
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer |
Non-small Cell Lung Cancer |
Recruiting |
2026-07-14 |
| NCT02821013 |
Duration of Anti-PD-1 Therapy in Metastatic Melanoma |
Unresectable/Metastatic Melanoma |
Recruiting |
2026-06-09 |
| NCT03550391 |
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy… |
Brain Metastases |
Recruiting |
2026-06-09 |
| NCT06439225 |
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With… |
Metastatic Castration-resistant Prostate Cancer |
Recruiting |
2026-04-16 |
| NCT06235697 |
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment |
Prostate Cancer |
Recruiting |
2026-04-14 |
| NCT03488693 |
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer |
Breast Cancer |
Active, Not Recruiting |
2026-07-01 |
| NCT04650581 |
Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive… |
Breast Cancer |
Active, Not Recruiting |
2026-04-13 |
| Phase 2/3 |
| NCT04093167 |
Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer |
Lung Cancer |
Active, Not Recruiting |
2026-07-31 |
| Phase 2 |
| NCT05640999 |
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer… |
Endometrial Cancer |
Recruiting |
2026-10-14 |
| NCT07341191 |
Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma… |
Mantle Cell Lymphoma |
Recruiting |
2026-10-14 |
| NCT03847649 |
A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior… |
Cancer |
Recruiting |
2026-09-15 |
| NCT05998642 |
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed… |
Non-hodgkin Lymphoma |
Recruiting |
2026-09-15 |
| NCT06623461 |
LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint… |
Melanoma |
Recruiting |
2026-09-15 |
| NCT06043427 |
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal… |
Gastroesophageal Adenocarcinoma |
Recruiting |
2026-08-11 |
| NCT06880523 |
STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable… |
Hepatocellular Carcinoma |
Recruiting |
2026-08-11 |
| NCT04918186 |
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer |
Ovarian Cancer |
Recruiting |
2026-07-21 |
| NCT05601440 |
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2… |
Breast Cancer |
Recruiting |
2026-05-07 |
| NCT03297606 |
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) |
Lymphoma, Non-Hodgkin |
Recruiting |
2026-03-27 |
| NCT05180097 |
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for… |
Hodgkin Lymphoma |
Recruiting |
2026-02-02 |